Sunovion Pharmaceuticals Inc. and Novartis AG signed an exclusive license agreement for U.S. commercialization rights to three approved chronic obstructive pulmonary disease drugs.
Under the deal, Sunovion will hold exclusive commercialization rights to Utibron Neohaler, Seebri Neohaler and Arcapta Neohaler in the U.S. Novartis will continue to manufacture the three drugs.
The U.S. FDA approved Utibron Neohaler and Seebri Neohaler in 2015. Sunovion plans to bring these two drugs to market in 2017. Arcapta Neohaler was approved in the U.S. in 2011 and arrived in the market in 2012.
Sunovion Pharmaceuticals is a unit of Sumitomo Dainippon Pharma Co. Ltd.